You are here

Article Text

Article menu

Download PDFPDF

XML
Crystal arthropathies
Original research
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
  1. Rachel Murdoch1,
  2. Michael J Barry2,
  3. Hyon K Choi3,
  4. Daniel Hernandez4,
  5. Brianne Johnsen3,
  6. Manuel Labrador5,
  7. Susan Reid1,
  8. Jasvinder A Singh6,7,
  9. Robert Terkeltaub8,
  10. Janitzia Vázquez Mellado5 and
  11. Nicola Dalbeth1
  1. 1Department of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
  2. 2Department of Primary Care, Harvard Medical School, Boston, Massachusetts, USA
  3. 3Division of Rheumatology Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA
  4. 4Global Healthy Living Foundation, Upper Nyack, New York, USA
  5. 5Department of Rheumatology, Hospital General de México, Ciudad de Mexico, Mexico
  6. 6Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
  7. 7Medicine Service, Birmingham VA Medical Center, Birmingham, Alabama, USA
  8. 8Department of Rheumatology, University of California San Diego, La Jolla, California, USA
  1. Correspondence to Dr Nicola Dalbeth; n.dalbeth{at}auckland.ac.nz

Abstract

Objective To develop a Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout, with the goal of increasing public understanding and awareness, and ensure consistent and understandable messages about gout.

Methods A G-CAN working group that included patients, physicians and nongovernmental organisation (NGO) representatives was formed to develop a common language definition of gout for use with the public, media, healthcare providers and stakeholders. A literature search and interviews with patients, healthcare workers and stakeholders informed development of the definition. Following consultation with G-CAN members and partners, the definition was endorsed by the G-CAN board.

Results The G-CAN common language definition of gout describes the epidemiology, pathophysiology, symptoms and impact, risk factors, comorbidities, management and healthcare and workforce considerations. Detailed information is provided to support the content of the definition. After the publication of the English-language version, the definition will be available for translation into other languages by G-CAN members.

Conclusion G-CAN has developed a concise and easily understandable statement describing gout in language that can be used in conversations with the lay public, media, NGOs, funders, healthcare providers and other stakeholders.

  • gout
  • crystal arthropathies
  • epidemiology

Data availability statement

Data are available upon reasonable request.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/rmdopen-2021-001623

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request.

    View Full Text

    Footnotes

    • Contributors All authors were part of the steering committee, contributed to the development of the protocol, reviewed all data and the common language definition and approved the final version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests ND reports personal fees and non-financial support from Abbvie, personal fees from Horizon, Janssen, Dyve, Selecta and Arthrosi, grants from Amgen, grants and personal fees from AstraZeneca and personal fees from Hengrui, outside the submitted work. G-CAN is a global gout research consortium, non-profit, supported at arms length by annual funding support from pharma. In the last 36 months, pharma donor support to G-CAN was provided by Horizon, Astra-Zeneca, SOBI, Takeda, CymaBay, Selecta and LG. RT reports other than from G-CAN, during the conduct of the study; personal fees from Astra-Zeneca, SOBI, Horizon, Selecta and grants from Astra-Zeneca, outside the submitted work. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio Health, Medscape, WebMD, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, Practice Point Communications, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in TPT Global Tech, Vaxart Pharmaceuticals and Charlotte’s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking and Moderna Pharmaceuticals. JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organisation that develops outcome measures in rheumatology and receives arms-length funding from 12 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is the chair of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Centre on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting. MJB reports grants from Healthwise, a non-profit, outside the submitted work.

    • Provenance and peer review Not commissioned; externally peer reviewed.